-
Naloxone Hydrochloride: Mechanism and Research Use
2026-09-13
Naloxone hydrochloride is a competitive opioid receptor antagonist used to interrogate μ-, δ-, and κ-opioid receptor signaling. This article connects its chemical specifications and receptor pharmacology with opioid addiction and withdrawal studies, while separating established evidence from product-reported neural stem cell proliferation modulation.
-
ICAA, RIP3, and Cardiac Hypertrophy
2026-09-12
A 2026 Cellular Signalling study identifies isochlorogenic acid A as a direct regulator of RIP3 in angiotensin II- and pressure overload-induced cardiac hypertrophy. Its central advance is the separation of RIP3-driven hypertrophic remodeling from canonical MLKL-dependent necroptosis, with the RIP3/CaMKII axis emerging as a mechanistically distinct target.
-
CA-074: Precision Cathepsin B Inhibition Workflows
2026-09-12
CA-074 enables selective interrogation of cathepsin B in biochemical assays, cell-death models, cancer metastasis, neurotoxicity, immune response modulation, and plant senescence research. This workflow-focused guide shows how to separate cathepsin B effects from broader cysteine-protease activity while improving dosing, controls, and troubleshooting.
-
DiD (DiDC 18 (5)) Plasma Membrane Probe
2026-09-11
DiD, also called DiDC 18 (5), is a red fluorescent lipophilic probe for plasma membrane labeling, live-cell tracking, and tissue imaging. Its 633 nm He-Ne excitation and longer-wavelength profile than DiI support imaging in samples with substantial intrinsic fluorescence, while fixation and permeabilization require localization controls.
-
TAK-715: From p38α Inhibition to Translation
2026-09-11
A mechanistic and translational perspective on TAK-715 as a selective p38 MAPK inhibitor, connecting cytokine biology, conformational kinase regulation, experimental design, and rheumatoid arthritis research without overstating preclinical evidence.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-10
This FASEB Journal study develops chemically modified p21 mRNA packaged in lipid nanoparticles for localized intravesical treatment of bladder cancer. The work links bladder-restricted protein expression with suppression of tumor growth in an orthotopic model, while defining a translational framework for tumor-suppressor replacement rather than conventional cytotoxic delivery.
-
TAI-1: Practical Hec1 Inhibitor Workflows
2026-09-10
TAI-1 combines potent mitotic disruption with practical workflows for viability, mechanism, combination, and tumor-suppressor studies. Its Hec1–Nek2 mechanism is especially useful for linking cancer cell proliferation inhibition to chromosomal misalignment and apoptotic cell death induction.
-
Praeruptorin A and NF-κB in Poly(I:C)-Activated Macrophages
2026-09-09
The reference study shows that Praeruptorin A suppresses poly(I:C)-induced inflammatory activation in RAW264.7 macrophages by reducing inflammatory gene expression and NF-κB pathway activity. Its combination of viability screening, RNA sequencing, pathway enrichment, and molecular validation provides a useful framework for studying natural-product regulation of TLR3-associated inflammation.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-09-09
Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and converted into epithelial monolayers containing metabolically functional enterocytes, creating a human-relevant platform for studying intestinal drug transport and metabolism.
-
HyperScribe™ Poly (A) Tailing Kit for ZGA RNA
2026-09-08
Discover how the HyperScribe™ Poly (A) Tailing Kit can strengthen controlled RNA rescue experiments inspired by HFM1-associated zygotic genome activation failure. This article connects RNA processing chemistry with assay design, controls, and interpretation without overstating clinical relevance.
-
VX-661: A Proteostasis-Aware CFTR Assay Guide
2026-09-07
VX-661 is a F508del CFTR corrector that restores trafficking and supports CFTR-mediated chloride channel activity. This guide translates calnexin-dependent variant biology into practical assay design, exposure sequencing, and interpretation strategies for cystic fibrosis research.
-
Alcian Blue & Nuclear Fast Red Staining Kit Guide
2026-09-07
Build a high-contrast workflow for acid mucins, cartilage-like matrix, and nuclear morphology with the Alcian Blue & Nuclear Fast Red Staining Kit pH2.5. The guide separates validated staining use from pre-analytical tissue-marking applications, helping researchers optimize mesenchymal stem cell assays and small tissue workflows without overinterpreting dye visibility.
-
Standardized Whole-Blood Stimulation and Immunometabolism
2026-09-05
Zhao and colleagues present a standardized fresh whole-blood stimulation protocol that combines immune challenges with targeted metabolic perturbation and cytokine measurement. The framework preserves multicellular and plasma interactions more effectively than isolated-cell assays, enabling comparative analysis of how metabolic pathways shape stimulus- and cytokine-specific immune responses.
-
GLI2–PRDX1 Ferroptosis Resistance in Bladder Cancer
2026-09-04
This study identifies a GLI2–PRDX1 transcriptional axis that suppresses ferroptosis and supports malignant progression in bladder cancer. Its mechanistic and drug-response data suggest that GLI2 inhibition may improve cisplatin sensitivity, while also defining important distinctions between ferroptosis research and RIP1-dependent necroptosis workflows.
-
MTT Assay Workflow for Cell Viability Research
2026-09-04
Learn how to use MTT as a practical metabolic activity measurement in cytotoxicity, proliferation, and radiation-triggered drug-delivery studies. This guide combines a reproducible workflow with controls and troubleshooting for interpreting formazan signals without overstating what the assay proves.